BPO 4% Gel

Manufacturer
Acella Pharmaceuticals, LLC | Harmony Labs, Inc.
Effective date
2018-09-27
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
9
Source
legacy-cache
Hydrated at
2026-08-02 00:49:19

Label at a glance#

ProductBPO
Active ingredientBenzoyl Peroxide
Label structure7 sections

Label contents#

Full prescribing information#

DESCRIPTION SECTION

BPO 4% Gel and BPO'8% Gel are topical preparations containing benzoyl peroxide 4% and 8%, respectively, as the active ingredient in a gel vehicle containing purified water, aloe barbadensis leaf juice, benzyl alcohOl, cetyl alcohol, dimethyl isosorbide, simethicone, stearyl alcohol and ceteareth-20.

CLINICAL PHARMACOLOGY SECTION

The exact method of action of benzoyl peroxide in acne vulgaris is not known. Benzoyd peroxide is an antibacterial agent with demonstrated activity against Propionibacterium acnes. This action, combined with the mild keratolytic effect of benzoyl peroxide is believed to be responsible for its usefulness in acne.Benzoyl peroxide is absorbed by the skin where it is metabolized to benzoic acid and excreted as benzoate in the urine.

INDICATIONS & USAGE SECTION

BPO 4% Gel and BPO 8% Gel are indicated for use in the topical treatment of mild to moderate acne vulgaris. BPO 4% Gel or BPO 8% Gel may be used as an addition in acne treatment regimens including antibiotics, retinoic acid products and sulfur/salicylic acid containing preparations.

CONTRAINDICATIONS SECTION

BPO 4% Gel and BPO 8% Gel should not be used in patients who have shown hypersensitivity to benzoyl peroxide or to any of the other ingredients in the product.

PRECAUTIONS SECTION

Contact sensitization reactions are associated with the use of topical benzoyl peroxide products and may be expected to occur in 10 to 25 of 1 000 patients. The most frequent adverse reactions associated with benzoyl peroxide use are excessive erythema and peeling which may be expected to occur in 5 of 100 patients. Excessive erythema and peeling most frequently appear during the initial phase of drug use and may normally be controlled by reducing frequency of use .

HOW SUPPLIED SECTION

BPO 4% Gel is supplied in 42.5 g (1.5 oz) tubes NDC42192-1 05-15. BPO 8% Gel is supplied in 42.5 9 (1.5 oz) tubes NDC 421 92-106-15.
Store at controlled room temperature 15°-30°C (59°·86°F).

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

TubeTubeU CartonU Carton

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
42192-105-15GM - Gram42192-1058827abc1-aef2-4d47-a457-951a4da65b1b12012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
42192-10542192-105-15

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
a78f5a10-5f56-46ad-ac99-b3f8eceef2a41f939cdb-bbac-49bb-972d-d85b0c1508372018-09-27Exact identifier
spl id: a78f5a10-5f56-46ad-ac99-b3f8eceef2a4
spl set id: 1f939cdb-bbac-49bb-972d-d85b0c150837

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.